Their test kits, which can be performed with a cheek-swab sample at any age, help men determine their risk for prostate cancer and identify high-risk individuals who would benefit most from screening. By offering a low-cost next-generation sequencing method, Stratify Genomics aims to improve patient outcomes and reduce healthcare costs associated with prostate cancer through modified screening frequency. The company was founded by a urologist who was concerned about delayed diagnoses and the increase in incurable disease due to controversies surrounding PSA screening.